Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.
Zhang, X., Song, F., Kuo, G.H., Xiang, A., Gibbs, A.C., Abad, M.C., Sun, W., Kuo, L.C., Sui, Z.(2011) Bioorg Med Chem Lett 21: 4762-4767
- PubMed: 21767952 
- DOI: https://doi.org/10.1016/j.bmcl.2011.06.067
- Primary Citation of Related Structures:  
3RO4 - PubMed Abstract: 
A series of indazoles have been discovered as KHK inhibitors from a pyrazole hit identified through fragment-based drug discovery (FBDD). The optimization process guided by both X-ray crystallography and solution activity resulted in lead-like compounds with good pharmaceutical properties.
Organizational Affiliation: 
Johnson & Johnson Pharmaceutical Research and Development, Welsh & McKean Roads, PO Box 776, Spring House, PA 19477, United States. xzhang5@its.jnj.com